Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose safety, tolerability, reactogenicity, and pharmacokinetic study of bapineuzumab (AAB 001) administered subcutaneously in subjects with mild to moderate AD.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Nov 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
28 Apr 2010 Planned end date changed from 1 Mar 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
28 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com